Taysha Gene Therapies (TSHA) Capital Expenditures (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Capital Expenditures of $24000.0 for Q1 2026, down 96.63% sequentially from $713000.0 in Q4 2025, and up 4.35% YoY from $23000.0 in Q1 2025.
Taysha Gene Therapies (TSHA) Capital Expenditures (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Capital Expenditures for 7 years, with the latest figure at $24000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 4.35% year-over-year to $24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $739000.0 (up 187.55% YoY) and the FY2025 annual result came in at $738000.0, up 97.33% from the prior year.
- Capital Expenditures eased to $24000.0 in Q1 2026 per TSHA's latest filing, from $713000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $20.6 million in Q4 2022 and troughed at -$3.4 million in Q3 2023.
- A 5-year average of $1.5 million and a median of $24000.0 in 2026 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures plunged 4869.57% in 2023, then soared 35750.0% in 2025.
- Over 5 years, Capital Expenditures stood at $20.6 million in 2022, then tumbled by 83.25% to $3.4 million in 2023, then slumped by 100.06% to -$2000.0 in 2024, then jumped by 35750.0% to $713000.0 in 2025, then plunged by 96.63% to $24000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $24000.0, $713000.0, and -$386000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 354,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 354,000.00 |
| Jun 30, 2026 | 354,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | 713,000.00 |
| Dec 31, 2025 | 713,000.00 |
| Sep 30, 2025 | -386,000.00 |
| Sep 30, 2025 | -386,000.00 |
| Jun 30, 2025 | 388,000.00 |
| Jun 30, 2025 | 388,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -69,000.00 |
| Sep 30, 2024 | -69,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Mar 31, 2024 | 140,000.00 |